Why Apple, Amazon, and Microsoft are Strong Buys
Last week, Apple (AAPL), Amazon (AMZN), and Microsoft (MSFT) posted quarterly results. MSFT stock rose the most and is the strongest stock to buy. In its fiscal third-quarter report, Microsoft reaffirmed its strength in sales of Azure solutions.Microsoft Azure benefited from the ongoing demand for AI services. The firm brought its capacity online faster than markets expected. As a result, shareholders should expect Azure AI services to grow by 16%-20% this year.Apple traded lower after posting results on May 1. Still, the firm introduced a new $100 billion share buyback program. In the last quarter, Apple earned $1.65 per share. Revenue increased by 5.1% Y/Y to $95.36 billion. iPhone sales accounted for $46.84 billion in revenue. Few shareholders are questioning Apple’s wisdom of buying back stock when the price-to-earnings are around 30 times. The firm could buy treasuries, earning 4.3% in interest income. The company’s confidence suggests that AAPL stock will bounce back in the next few weeks.Amazon posted revenue growing by 8.7% Y/Y to $155.7 billion. AWS sales grew by 17% Y/Y. Customers will want more AWS computing power. Amazon brought more P5 GPU instances online since February. It is buying more Nvidia (NVDA) chips to power its Tranium 2 systems. AMZN stock is a strong buy since AI demand results in triple-digit percentage revenue growth.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


